Evaluation of Long-term Immunogenicity of a Boost Dose of MVA-BN Vaccine
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Mar 13, 2025
Trial Information
Current as of April 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to understand how well a booster dose of the MVA-BN vaccine works over a long period of time in protecting against monkeypox. The researchers want to see if giving an extra dose of this vaccine can help maintain strong immunity in people who have already received two doses.
To join the study, participants need to be men over 18 years old who have already had two doses of the MVA-BN vaccine and are eligible for a booster shot, following specific health guidelines. They should also be planning to start or continue HIV prevention treatment and have social security coverage. The trial is not yet recruiting participants, but once it starts, those who qualify can expect to receive the booster dose and help researchers learn more about the vaccine's effectiveness. This study is important for improving our understanding of how to keep people safe from monkeypox.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men aged over 18 years
- • Have received two doses of MVA-BN vaccine as an initial schedule
- • Eligible for a booster dose of MVA-BN (according to the HAS recommendation)
- • Be eligible and wish to initiate PrEP-HIV treatment or be followed for PrEP-HIV treatment
- • Covered by social security (excluding AME)
- Exclusion Criteria:
- • History of mpox (virologically confirmed)
- • Be under guardianship or curatorship
- • Be subject to a judicial protection measure
- • Have a contraindication to vaccination against mpox
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Liem Binh Luong Nguyen, Degree medical doctor
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported